Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap ...
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...
Unlock access to every one of the hundreds of articles published daily on BroadwayWorld by logging in with one click. Co-Artistic Directors of Morphic Graffiti, Luke Fredericks and Stewart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback